Literature DB >> 28027454

Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers.

Semir Vranic1, Rebecca Feldman, Zoran Gatalica.   

Abstract

Apocrine carcinoma of the breast is a rare, primary breast cancer characterized by the apocrine morphology, estrogen receptor-negative and androgen receptor-positive profile with a frequent overexpression of Her-2/neu protein (~30%). Apart from the Her-2/neu target, advanced and/or metastatic apocrine carcinomas have limited treatment options. In this review, we briefly describe and discuss the molecular features and new theranostic biomarkers for this rare mammary malignancy. The importance of comprehensive profiling is highlighted due to synergistic and potentially antagonistic molecular events in the individual patients.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28027454      PMCID： PMC5341783          DOI： 10.17305/bjbms.2016.1811

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN： 1512-8601            Impact factor:   3.363


  21 in total

1.  A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).

Authors:  H Bonnefoi; T Grellety; O Tredan; M Saghatchian; F Dalenc; A Mailliez; T L'Haridon; P Cottu; S Abadie-Lacourtoisie; B You; M Mousseau; J Dauba; F Del Piano; I Desmoulins; F Coussy; N Madranges; J Grenier; F C Bidard; C Proudhon; G MacGrogan; C Orsini; M Pulido; A Gonçalves
Journal:  Ann Oncol       Date:  2016-02-18       Impact factor: 32.976

Review 2.  Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.

Authors:  Claudia Arce-Salinas; Maria Carmen Riesco-Martinez; Wedad Hanna; Philippe Bedard; Ellen Warner
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 44.544

3.  Androgen and estrogen receptor mRNA status in apocrine carcinomas.

Authors:  Gary L Bratthauer; Ruth A Lininger; Yan-gao Man; Fattaneh A Tavassoli
Journal:  Diagn Mol Pathol       Date:  2002-06

4.  Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Authors:  W Shi; T Jiang; P Nuciforo; C Hatzis; E Holmes; N Harbeck; C Sotiriou; L Peña; S Loi; D D Rosa; S Chia; A Wardley; T Ueno; J Rossari; H Eidtmann; A Armour; M Piccart-Gebhart; D L Rimm; J Baselga; L Pusztai
Journal:  Ann Oncol       Date:  2017-01-01       Impact factor: 32.976

5.  Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.

Authors:  Semir Vranic; Caterina Marchiò; Isabella Castellano; Cristina Botta; Maria Stella Scalzo; Ryan P Bender; Cesar Payan-Gomez; Ludovica Verdun di Cantogno; Patrizia Gugliotta; Fabrizio Tondat; Paola Francia di Celle; Sara Mariani; Zoran Gatalica; Anna Sapino
Journal:  Hum Pathol       Date:  2015-06-05       Impact factor: 3.466

Review 6.  Apocrine carcinoma of the breast: a comprehensive review.

Authors:  Semir Vranic; Fernando Schmitt; Anna Sapino; Jose Luis Costa; Sandeep Reddy; Michael Castro; Zoran Gatalica
Journal:  Histol Histopathol       Date:  2013-06-17       Impact factor: 2.303

7.  A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer.

Authors:  Ali Naderi; Luke Hughes-Davies
Journal:  Neoplasia       Date:  2008-06       Impact factor: 5.715

8.  Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers.

Authors:  Anne M Mills; Chelsea E Gottlieb; Scott M Wendroth; Christiana M Brenin; Kristen A Atkins
Journal:  Am J Surg Pathol       Date:  2016-08       Impact factor: 6.394

9.  Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.

Authors:  Upasana Joneja; Semir Vranic; Jeffrey Swensen; Rebecca Feldman; Wangjuh Chen; Jeffrey Kimbrough; Nianqing Xiao; Sandeep Reddy; Juan Palazzo; Zoran Gatalica
Journal:  J Clin Pathol       Date:  2016-08-16       Impact factor: 3.411

10.  PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.

Authors:  Brian D Lehmann; Joshua A Bauer; Johanna M Schafer; Christopher S Pendleton; Luojia Tang; Kimberly C Johnson; Xi Chen; Justin M Balko; Henry Gómez; Carlos L Arteaga; Gordon B Mills; Melinda E Sanders; Jennifer A Pietenpol
Journal:  Breast Cancer Res       Date:  2014-08-08       Impact factor: 6.466
View more
  6 in total

Review 1.  Apocrine lesions of the breast.

Authors:  Cecily M Quinn; Clare D'Arcy; Clive Wells
Journal:  Virchows Arch       Date:  2021-09-18       Impact factor: 4.535

2.  Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.

Authors:  Wenyu Wu; Meiying Wu; Guowen Peng; Degang Shi; Jian Zhang
Journal:  Cancer Med       Date:  2019-10-23       Impact factor: 4.452

3.  HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome.

Authors:  Faruk Skenderi; Mohamad Alhoda Mohamad Alahmad; Emin Tahirovic; Yaman M Alahmad; Zoran Gatalica; Semir Vranic
Journal:  Breast Cancer Res Treat       Date:  2022-03-30       Impact factor: 4.624

Review 4.  Histology of Luminal Breast Cancer.

Authors:  Ramona Erber; Arndt Hartmann
Journal:  Breast Care (Basel)       Date:  2020-07-15       Impact factor: 2.860

5.  Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions.

Authors:  Koichi Kubouchi; Kyosuke Shimada; Takamichi Yokoe; Yutaka Tsutsumi
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

6.  Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis.

Authors:  Francesca Sanges; Matteo Floris; Paolo Cossu-Rocca; Maria R Muroni; Giovanna Pira; Silvana Anna Maria Urru; Renata Barrocu; Silvano Gallus; Cristina Bosetti; Maurizio D'Incalci; Alessandra Manca; Maria Gabriela Uras; Ricardo Medda; Elisabetta Sollai; Alma Murgia; Dolores Palmas; Francesco Atzori; Angelo Zinellu; Francesca Cambosu; Tiziana Moi; Massimo Ghiani; Vincenzo Marras; Maria Cristina Santona; Luisa Canu; Enrichetta Valle; Maria Giuseppina Sarobba; Daniela Onnis; Anna Asunis; Sergio Cossu; Sandra Orrù; Maria Rosaria De Miglio
Journal:  BMC Cancer       Date:  2020-06-02       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.